Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)
NCT02798354 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13853
Last updated 2019-12-16
Summary
The proposal will focus on 3 specific, high-risk, pediatric ambulatory diagnostic errors each representing a unique dimension of diagnostic assessment: evaluation of symptoms, evaluation of signs and follow-up of diagnostic tests. Adolescent depression (i.e. symptoms) affects nearly 10% of teenagers, is misdiagnosed in almost 75% of adolescents and causes significant morbidity. Pediatric elevated blood pressure (signs) is misdiagnosed in 74-87% of patients, often due to inaccurate application of blood pressure parameters that change based on age, gender and height. Actionable pediatric laboratory values (diagnostic tests) are potentially delayed up to 26% of the time in preliminary investigations and 7-65% in adults, leading to harm and malpractice claims.
The investigators propose to conduct a multisite, prospective, stepped wedge cluster randomized trial testing a quality improvement collaborative (QIC) intervention within the American Academy of Pediatrics' Quality Improvement Innovation Networks (QuIIN) to reduce the incidence of pediatric primary care diagnostic errors. QuIIN is a national network of over 300 primary care practices, ranging from tertiary care academic medical centers to single practitioner private practices, interested in and experienced with QICs. Because many processes are likely to be common across diagnostic errors in outpatient settings, a multifaceted intervention, such as a QIC, has a high likelihood of success and broad applicability across populations. Preparatory inquiries to QuIIN primary care providers suggest high interest in reducing these 3 diagnostic errors and provider agreement with randomization to evaluate diagnostic error interventions. Practices will be randomized to one of three groups, with each group collecting retrospective baseline data on one error above, and then intervening to reduce that error during the first eight months. Each group will concurrently collect control data on an error they are not intervening on during those eight months. Following those eight months, the groups will continue intervening on their first error, begin intervening on the error they were a control site for, and begin collecting data on the third error for which they will be a control site for. Finally, in the final eight months, all groups will intervene on all three errors. A second wave of practices will be recruited to join the groups after eight months and will only intervene on two of the three errors.
Conditions
- Diagnostic Errors
Interventions
- BEHAVIORAL
-
Quality Improvement Collaborative
1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
Sponsors & Collaborators
-
American Academy of Pediatrics
collaborator OTHER -
Montefiore Medical Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 26 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-01
- Primary Completion
- 2017-10-31
- Completion
- 2017-10-31
Countries
- United States
Study Locations
More Related Trials
-
Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE
NCT07199894 ·Status: RECRUITING ·Phase: PHASE3
-
BLOOM: Biological Legacy of Origin in Mother-Infant Dyads
NCT02000895 ·Status: RECRUITING
-
Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome
NCT02368379 ·Status: COMPLETED ·Phase: NA
-
Pediatric Cardiomyopathy Mutation Analysis
NCT02432092 ·Status: RECRUITING
-
Desmopressin Melt: Impact on Sleep and Daytime Functioning
NCT01645475 ·Status: COMPLETED ·Phase: PHASE4
-
Rescue of Infants With MCT8 Deficiency
NCT04143295 ·Status: AVAILABLE
-
Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status
NCT01629940 ·Status: COMPLETED
-
Genetics of Congenital Heart Disease
NCT01192048 ·Status: RECRUITING
-
Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease
NCT02636387 ·Status: TERMINATED
-
Steroid Treatment of Idiopathic Nephrotic Syndrome
NCT01386957 ·Status: COMPLETED
-
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
NCT04217421 ·Status: RECRUITING ·Phase: PHASE3
-
Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease
NCT00208676 ·Status: TERMINATED
-
Outcomes of Children With Congenital Single Ventricle Heart
NCT00266968 ·Status: COMPLETED
-
Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients
NCT05671666 ·Status: RECRUITING ·Phase: NA
-
At Home Ammonia Monitoring of Inborn Errors of Ammonia Metabolism
NCT06953505 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse
NCT02216747 ·Status: UNKNOWN ·Phase: PHASE4
-
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
NCT04338048 ·Status: RECRUITING
-
Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study
NCT01439997 ·Status: COMPLETED ·Phase: PHASE4
-
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
NCT02602769 ·Status: RECRUITING
-
Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NCT02132195 ·Status: COMPLETED ·Phase: PHASE3
-
Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients
NCT00249067 ·Status: TERMINATED
-
Implementation of a Diagnostic Workflow for Personalized Diagnosis of Nephrotic Syndrome
NCT06325098 ·Status: RECRUITING ·Phase: NA
-
Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia
NCT01373372 ·Status: WITHDRAWN ·Phase: NA
-
CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
NCT03786263 ·Status: UNKNOWN
-
Critical Congenital Heart Defect (CHD) Outcomes in Children
NCT00208689 ·Status: TERMINATED